Latest information on baricitinib manufacturers and prices

Baricitinib (Baricitinib), as an oral selective tyrosine protein kinase (JAK) 1 and JAK2 inhibitor, has achieved remarkable results in the treatment of moderate to severe active rheumatoid arthritis and other autoimmune diseases in recent years. With the continuous expansion of its clinical application, the manufacturer and price information of baricitinib have become the focus of attention of patients and medical professionals.

The original drug of baricitinib is developed and produced by Eli Lilly, a world-renowned pharmaceutical company. Currently in the Chinese market, the price of a box of original medicine is approximately more than 1,000 yuan. Please check with your local pharmacy or pharmacy for details. In addition, the drug has been included in medical insurance, and eligible patients can enjoy reimbursement benefits.

In addition to original drugs, there are also many generic drug manufacturers on the market. For example, pharmaceutical companies in Bangladesh and other countries have launched generic versions of baricitinib. The price of these generic drugs is usually more affordable than the original drugs, which can alleviate a lot of financial pressure on patients. For example, the generic version is about 200 per box, and the Yaopin international version is about 500 per box.

In addition, when purchasing baricitinib, in addition to paying attention to the price, patients should also pay attention to purchasing through regular channels to ensure the quality and efficacy of the drug. It is recommended that patients take medication under the guidance of a doctor and follow the doctor's instructions to adjust the dosage and medication cycle.

In summary, baricitinib is an important drug for the treatment of autoimmune diseases, and its manufacturer and price information are crucial for patients and medical professionals. With the continuous expansion of the generic drug market and the gradual implementation of policies, the price of baricitinib is expected to be further reduced in the future, providing patients with more choices and better treatment protection.